US · TELA
TELA Bio, Inc.
- Sector
- Healthcare · Medical - Devices
- Headquarters
- Malvern, PA 19355
- Website
- telabio.com
Price · as of 2024-12-31
$0.99
Market cap 38.66M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $24.91 | +2,418.45% |
| Intrinsic Value(DCF) | $0.97 | -1.93% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | |||||
| 2011 | |||||
| 2012 | |||||
| 2013 | |||||
| 2014 | |||||
| 2015 | |||||
| 2016 | |||||
| 2017 | |||||
| 2018 | $0.00 | $0.00 | |||
| 2019 | $14.90 | $35.47 | $9,890.43 | $0.00 | $0.00 |
| 2020 | $16.40 | $29.60 | $2.73 | $0.00 | $0.00 |
| 2021 | $11.95 | $29.26 | $169.26 | $0.00 | $0.00 |
| 2022 | $10.10 | $23.32 | $45.32 | $0.00 | $0.00 |
| 2023 | $5.74 | $26.75 | $110.21 | $0.00 | $0.00 |
| 2024 | $2.42 | $24.91 | $6.59 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates TELA Bio, Inc.'s (TELA) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $24.91
- Current price
- $0.99
- AI upside
- +2,418.45%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$0.97
-1.93% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| TELA | TELA Bio, Inc. | $0.99 | 38.66M | +2,418% | -2% | — | — | -1.82 | 2.43 | 1.00 | -1.88 | — | 2.58 | 67.08% | -49.23% | -54.60% | -159.87% | -201.31% | -45.76% | 1.51 | -6.45 | 5.01 | 4.02 | 0.30 | -3480.00% | 1856.00% | 269.00% | -61.69% | -2.67 | -252.24% | 0.00% | 0.00% | 8.18% | -1.74 | -1.40 | 0.86 | -4.68 |
| COEP | Coeptis Therapeutics, Inc… | $12.04 | 42.29M | — | — | — | — | -1.87 | 6.40 | — | -2.25 | -0.32 | 7.72 | 0.00% | — | — | -290.10% | -247.64% | -128.12% | 0.44 | -25.38 | 0.23 | 0.12 | -0.09 | 58072.00% | — | -815.00% | -32.60% | -1.47 | -163.77% | 0.00% | 0.00% | 0.00% | -2.11 | -3.20 | — | -17.20 |
| CTSO | Cytosorbents Corporation | $0.75 | 47.26M | +3,558% | -47% | — | — | -2.65 | 4.95 | 1.54 | -5.17 | — | 7.47 | 70.59% | -47.16% | -58.21% | -120.52% | -49.92% | -41.18% | 2.42 | -12.00 | 2.20 | 1.08 | -1.55 | -4154.00% | 1451.00% | -3488.00% | -26.76% | -1.47 | -47.32% | 0.00% | 0.00% | 0.00% | -4.68 | -5.34 | 2.21 | -8.19 |
| CUE | Cue Biopharma, Inc. | $0.28 | 22.08M | +11,310% | +57% | — | — | -1.52 | 3.54 | 6.67 | -1.26 | — | 3.54 | 100.00% | -446.86% | -437.97% | -149.03% | -1327.36% | -86.80% | 0.51 | -52.14 | 1.84 | 1.78 | 0.36 | -3514.00% | 6916.00% | -892.00% | -58.74% | -2.65 | -1164.08% | 0.00% | 0.00% | 0.00% | -1.14 | -1.30 | 5.11 | -15.88 |
| EQ | Equillium, Inc. | $1.82 | 64.65M | +1,406% | -79% | — | — | -3.51 | 1.48 | 0.69 | -0.81 | — | 1.48 | 100.00% | -20.12% | -19.63% | -38.75% | 80.29% | -21.19% | 0.02 | — | 3.93 | 3.73 | 2.34 | -3947.00% | 1389.00% | -1247.00% | -67.56% | -2.99 | 185.55% | 0.00% | 0.00% | 0.00% | -0.74 | -0.32 | 0.15 | -6.59 |
| ICCM | IceCure Medical Ltd | $0.58 | 39.85M | +4,441% | -7% | — | — | -4.48 | 9.95 | 20.87 | -4.01 | — | 9.95 | 44.09% | -476.94% | -465.45% | -160.70% | -2098.40% | -105.69% | 0.07 | — | 1.95 | 1.41 | 0.46 | -625.00% | 192.00% | -282.00% | -18.39% | -2.28 | -1689.04% | 0.00% | 0.00% | 0.00% | -3.92 | -4.87 | 18.71 | -7.83 |
| MDAI | Spectral AI, Inc. | $1.40 | 42.96M | +2,693% | -59% | — | — | -1.69 | -3.56 | 0.87 | -2.21 | — | -3.56 | 44.87% | -22.25% | -51.77% | 341.85% | 101.83% | -134.42% | -0.65 | -2.22 | 0.57 | 0.43 | 0.04 | -4257.00% | 6383.00% | -3052.00% | -35.62% | -0.52 | 142.31% | 0.00% | 0.00% | 0.00% | -3.85 | -2.76 | 0.86 | -4.86 |
| NRXP | NRx Pharmaceuticals, Inc. | $1.86 | 32.15M | — | — | — | — | -0.91 | -0.98 | — | -1.16 | — | -0.98 | 0.00% | — | — | 143.76% | 156.03% | -458.25% | -0.28 | -18.26 | 0.15 | 0.07 | -0.21 | -3995.00% | — | -5089.00% | -46.61% | -0.49 | 84.23% | 0.00% | 0.00% | 0.00% | -1.42 | -2.63 | — | -130.11 |
| OTLK | Outlook Therapeutics, Inc… | $0.42 | 17.31M | — | +90,898,778% | — | — | 0.00 | 0.00 | 50.46 | 123242.30 | — | 0.00 | 46.49% | -4744.25% | -4416.22% | 387.88% | 0.00% | -671.81% | -0.01 | -236.86 | 0.38 | 0.18 | 123243.42 | -5591.00% | — | 7534010988.00% | -72659652.79% | -1.13 | 259.00% | 0.00% | 0.00% | 10984444.51% | 116837.47 | 0.15 | -5543064.49 | -47.47 |
| SPRB | Spruce Biosciences, Inc. | $54.94 | 31.88M | +1,366% | +1,346% | — | +7,284% | -20.08 | 36.96 | 216.90 | -19.54 | -498.08 | 36.96 | 100.00% | -1143.37% | -1079.94% | -100.70% | 501.62% | -71.12% | 0.10 | -182.90 | 2.90 | 2.54 | 0.68 | 403.00% | -5132.00% | 6815.00% | -5.25% | -3.67 | 499.95% | 0.00% | 0.00% | 0.00% | -18.33 | -18.39 | 209.57 | 28.03 |
| SRTS | Sensus Healthcare, Inc. | $4.11 | 67.51M | +2,671% | -38% | -86% | +183% | -9.71 | 1.56 | 2.73 | -5.40 | — | 1.56 | 43.18% | -37.50% | -28.09% | -14.85% | -27.07% | -13.40% | 0.01 | — | 9.72 | 5.96 | 2.16 | -21463.00% | -3426.00% | -10000.00% | 0.00% | 0.00 | 0.00% | 0.00% | 0.00% | 0.00% | -5.19 | — | 1.95 | 10.06 |
About TELA Bio, Inc.
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. It provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. The company markets its products through a single direct sales force, principally in the United States. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
- CEO
- Antony Koblish
- Employees
- 209
- Beta
- 0.87
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($0.97 ÷ $0.99) − 1 = -1.93% (DCF, example).